MAJOR NEWS ABOUT ANIFROLUMAB AS POTENTIAL NEW LUPUS TREATMENT
 |
MOMENTOUS NEWS -- Potential New Lupus Treatment Effectively Reduced Disease Activity in Phase III Trial
The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. More than 15 studies funded by the Lupus Research Alliance over the past decade into the role of type I interferons and inflammation were pivotal to the eventual development of anifrolumab.
“It is tremendously gratifying to learn of this important success,” commented Dr. Mary Crow, Co-chair of the Lupus Research Alliance Scientific Advisory Board (SAB) and Physician-in-Chief/Chair of Department of Medicine at Hospital for Special Surgery and Chief of Rheumatology at HSS and NewYork-Presbyterian/Weill Cornell Medical Center. “The Lupus Research Alliance has made significant investments in research focused on the role of type I interferons in lupus, and I am personally very excited given my own research in this area.”
Lupus Research Alliance President and CEO Kenneth M. Farber noted, “These positive results from a pivotal Phase III trial are very hopeful for people with lupus who have waited years for desperately needed new treatment options. We look forward to seeing the full results of the study and further progress in evaluating anifrolumab as a potential therapy.”
From the Lupus Research Alliance, the world’s leading authority in lupus research.
|
 |
   
Lupus Research Alliance is a 501(c)(3) organization, contributions to which are tax-deductible as permitted by law. Tax ID 58-2492929.
100% of all donations goes to support lupus research programs because the Lupus Research Alliance Board of Directors funds all administrative and fundraising costs.
© 2019 Lupus Research Alliance. All rights reserved.
 |
